* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Dopamine-Independent Locomotion Following Blockade of N
Signal transduction wikipedia , lookup
Long-term depression wikipedia , lookup
Neuromuscular junction wikipedia , lookup
Caridoid escape reaction wikipedia , lookup
Activity-dependent plasticity wikipedia , lookup
Metastability in the brain wikipedia , lookup
Environmental enrichment wikipedia , lookup
Neuroanatomy wikipedia , lookup
Neural oscillation wikipedia , lookup
Synaptogenesis wikipedia , lookup
Development of the nervous system wikipedia , lookup
Aging brain wikipedia , lookup
Biology of depression wikipedia , lookup
Central pattern generator wikipedia , lookup
Feature detection (nervous system) wikipedia , lookup
Stimulus (physiology) wikipedia , lookup
Embodied language processing wikipedia , lookup
Time perception wikipedia , lookup
Pre-Bötzinger complex wikipedia , lookup
Basal ganglia wikipedia , lookup
Channelrhodopsin wikipedia , lookup
Endocannabinoid system wikipedia , lookup
Neurotransmitter wikipedia , lookup
Optogenetics wikipedia , lookup
Premovement neuronal activity wikipedia , lookup
Molecular neuroscience wikipedia , lookup
Neuroeconomics wikipedia , lookup
Synaptic gating wikipedia , lookup
NMDA receptor wikipedia , lookup
0022-3565/01/2981-226 –233$3.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics JPET 298:226–233, 2001 Vol. 298, No. 1 3583/911044 Printed in U.S.A. Dopamine-Independent Locomotion Following Blockade of N-Methyl-D-aspartate Receptors in the Ventral Tegmental Area JENNIFER L. CORNISH,1 MISTU NAKAMURA, and PETER W. KALIVAS Department of Physiology and Neuroscience, Medical University of South Carolina, Charleston, South Carolina Received November 21, 2000; accepted March 13, 2001 This paper is available online at http://jpet.aspetjournals.org A role for the mesocorticolimbic dopamine projection has been proposed for a number of psychiatric disorders, including schizophrenia and drug addiction (Robinson and Berridge, 1993; Yang et al., 1999). The mesocorticolimbic dopamine system arises from dopaminergic neurons in the ventral tegmental area (VTA), which send axonal projections to a number of forebrain nuclei such as the nucleus accumbens and prefrontal cortex (Fallon and Moore, 1978). As a result of the therapeutic interest, characterizing afferent regulation of dopamine cells in the VTA has been a research focus for over two decades (for review, see Kalivas, 1993). Arising from these investigations is the demonstration that glutamatergic afferents to the VTA provide potent excitation of dopamine neurons (Johnson et al., 1992; Smith et al., 1996). Excitation This work was supported in part by U.S. Public Health Service Grants DA-03906 and MH-40817. 1 Current address: Department of Psychobiology, National Institute on Drug Abuse/National Institutes of Health Building C, Room 321, 5500 Nathan Shock Dr., Baltimore, MD 21224. E-mail: [email protected] 2) Stimulating orphanin receptors in the ventral tegmental area selectively inhibits dopamine cells, and this did not alter NMDA antagonist-induced motor activity. Whereas, stimulating ␥-aminobutyric acid (GABA)B receptors hyperpolarizes both dopamine and GABA cells in the ventral tegmental area, and this abolished NMDA antagonist-induced motor activity. 3) The microinjection of an NMDA antagonist into the ventral tegmental area did not increase dopamine metabolism in dopamine terminal fields, including the accumbens, striatum, or prefrontal cortex. Also consistent with a lack of dopamine involvement, repeated administration of NMDA antagonist into the ventral tegmental area did not produce behavioral sensitization. These data identify a mechanism to elicit a motor stimulant response from the ventral tegmental area that does not involve activating dopamine transmission. of dopamine cells in the VTA is associated with behavioral activation (Kalivas, 1993; Robinson and Berridge, 1993). Accordingly, pharmacological stimulation of ionotropic or metabotropic glutamate receptors in the VTA elicits an increase in exploratory motor behavior and promotes the release of dopamine in mesocorticolimbic axon terminal fields in the ventral striatum and prefrontal cortex (Suaud-Chagny et al., 1992; Swanson and Kalivas, 2000). However, some laboratories (Kalivas and Alesdatter, 1993; Narayanan et al., 1996; Vezina and Queen, 2000), but not others (Kretschmer, 1999) have shown that blockade of the NMDA glutamate receptor subtype in the VTA also stimulates motor activity. The present study was designed to further investigate the capacity of NMDA and non-NMDA glutamate receptor antagonists to produce a motor stimulant response when microinjected into the VTA. Two populations of neurons can be distinguished in the VTA, dopaminergic and GABAergic neurons (Johnson et al., 1992). The dopaminergic and a portion of the GABAergic ABBREVIATIONS: VTA, ventral tegmental area; NMDA, N-methyl-D-aspartate; GABA, ␥-aminobutyric acid; AMPA, ␣-amino-3-hydroxy-5-methyl4-isoxazolepropionic acid; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; AP-5, 2-amino-5-phosphonopentanoic acid; MCPG, (S)-␣-methyl-4carboxyphenylglycine; CPP, (3-(R)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid; DAMGO, D-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin; OFQ, orphanin FQ-nociceptin; DOPAC, 3,4-dihydroxyphenyl acetic acid; HVA, homovanillic acid; ANOVA, analysis of variance; mGluR, metabotropic glutamate receptor. 226 Downloaded from jpet.aspetjournals.org at ASPET Journals on May 5, 2017 ABSTRACT Compounds acting in the ventral tegmental area to increase motor activity are thought to do so by activating mesolimbic dopamine transmission. The present report demonstrates that the microinjection of N-methyl-D-aspartate (NMDA) antagonists into the ventral tegmental area produces a dose-dependent increase in motor activity. This effect was not mimicked by antagonizing either ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate or metabotropic glutamate receptors in the ventral tegmental area. Three experiments were conducted that indicated that the capacity of NMDA receptor antagonists to elevate motor activity did not involve increased dopamine transmission. 1) The systemic administration of a D1 dopamine receptor antagonist did not inhibit the motor stimulant response to NMDA antagonist injection into the ventral tegmental area except at doses that also inhibited motor activity after an injection of saline into the ventral tegmental area. NMDA Antagonists in VTA Materials and Methods Animal Housing and Surgery. All experiments were conducted according to specifications of the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) weighing between 250 and 300 g were individually housed with food and water available ad libitum. A 12-h light/dark cycle (7:00 AM–7:00 PM light) was used to regulate the animal photocycle. All experimentation was carried out during the light cycle. Surgeries were performed 5 to 7 days after the arrival of the subjects to the ALAC-approved housing facility and all experimentation began 1 week following the operative procedure. Animals were anesthetized using ketamine HCl (100 mg/kg, Ketaset; Fort Dodge Animal Health, Fort Dodge, IA) and xylazine (12 mg/kg, Rompun; Bayer, Shawnee Mission, KS) and chronic indwelling guide cannulae (26-gauge, 14 mm; Small Parts, Roanoke, VA) were aimed 1 mm above injection site in the VTA (A-P, ⫹2.5 mm; L-M, ⫾0.6 mm; D-V, ⫺1.5 mm, from interaural zero angled 6o from the midline in accordance with Pellegrino et al., 1979). The guide cannulae were fixed to the skull with three stainless steel screws (Small Parts) and dental acrylic, and were fit with obturators (33-gauge, 14 mm; Small Parts) between testing periods to prevent blockage by debris. Drugs. All glutamate receptor antagonists used in this study were purchased from Tocris Cookson (St. Louis, MO), including 6-cyano-7nitroquinoxaline-2,3-dione (CNQX), 2-amino-5-phosphonopentanoic acid (AP-5), (S)-␣-methyl-4-carboxyphenylglycine (MCPG), and (3-(R)2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP). The D1 dopamine receptor antagonist (R)-SCH-23390 HCl and the -opioid receptor agonist {[D-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin (DAMGO)} were purchased from RBI/Sigma (Natick, MA), and orphanin FQ-nociceptin (OFQ) was a gift from Dr. David Grandy (Vollum Institute, Portland, OR). All drugs were dissolved in sterile isotonic saline except CNQX, which was dissolved in dimethyl sulfoxide and diluted in sterile water to a 10% dimethyl sulfoxide solution. All drugs except SCH-23390 were made up in bulk volume and stored at ⫺80°C. For all intracranial injections, nanomolar concentrations represent the total amount administered per bilateral injection. Microinjection and Experimental Design. Immediately prior to testing, the obturators were removed and the injection cannulae (33-gauge, 15 mm) fitted to a 1-l Hamilton syringe by PE-20 tubing were inserted to a depth 1 mm below the tip of the guide cannula. Bilateral infusions were made over 60 s in a total volume of 0.5 l/side. The infusion pump was turned off and the injection cannulae were left in place for an additional 60 s to prevent backflow of drug at which time animals were placed into the photocell cages (Omnitech, Columbus, OH). Twenty-four hours prior to the first microinjection, animals were preadapted to the photocell apparatus for 1 h, given a sham microinjection (needle inserted but no injection made), and returned to the photocell cage for another hour. Each test period consisted of a 1-h habituation where animals were placed in photocell cages prior to testing. Following microinfusion, motor activity was monitored in 15-min intervals for 2 h. Animals were returned to their home cages at the close of each session and left undisturbed for 2 days following each test day to ensure clearance of drug and recovery from the microinjection procedure. All experiments used a counterbalanced design across days over the complete test period, resulting in each animal receiving a maximum of six microinjections. For the sensitization study, rats were microinjected into the VTA with saline (N ⫽ 13) or CPP (0.03 nmol, N ⫽ 11, or 0.1 nmol, N ⫽ 17) once a day for 3 days. All injections were made in the photocell apparatus. One week later all animals were microinjected with CPP (0.1 nmol) and 1 to 2 weeks later all rats were injected with cocaine (15 mg/kg i.p.). Motor activity was monitored in clear Plexiglas boxes measuring 22 ⫻ 43 ⫻ 33 cm. A series of 16 photobeams (eight on each horizontal axis) tabulated horizontal movements, whereas a series of eight beams located 8 cm above the floor spanned each box to vertical activity (rearing). Photobeam breaks were recorded by computer interface and the data was stored after each test day. Total horizontal activity, distance traveled (an estimate of locomotion where only consecutive breaking of adjacent photocell beams is quantified), and vertical activity (an estimate of rearing behavior) were monitored during each test period. Measurement of Dopamine and Metabolites. Subjects were microinjected with AP-5 (5.0 nmol), DAMGO (0.1 nmol), or saline into the VTA, placed in a photocell box to monitor motor activity, and decapitated 30 min after injection. The nucleus accumbens, striatum, and prefrontal cortex were dissected (Latimer et al., 1987) and the levels of dopamine and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured using high-performance liquid chromatography with electrochemical detection as described elsewhere (Latimer et al., 1987). Peak heights were measured and normalized to the internal standard isoproterenol for data analysis. Downloaded from jpet.aspetjournals.org at ASPET Journals on May 5, 2017 neurons project out of the VTA (Fallon and Moore, 1978; Thierry et al., 1980; Van Bockstaele and Pickel, 1995; Steffensen et al., 1998). The remainder of the GABAergic cells are interneurons that provide inhibitory tone onto dopamine cells (Johnson et al., 1992). Pharmacologically stimulating a variety of neurotransmitter receptors in the VTA elicits a motor stimulant response, including -opioid, neurotensin, Substance P, ionotropic glutamate (NMDA, AMPA, and kainate subtypes), and GABAA receptors (for review, see Kalivas, 1993). In all instances, the motor stimulant response has been shown to be blocked by dopamine receptor antagonists and/or associated with enhanced dopamine transmission in the nucleus accumbens (Kelley et al., 1979; Cador et al., 1989; Yoshida et al., 1997). Thus, to date the initiation of motor activity by modulating neurotransmission in the VTA is dopamine-dependent, arising from either a direct activation of dopamine neurons or disinhibition of dopamine cells by inhibiting GABAergic interneurons (Kalivas, 1993). The present study investigated whether the activation of motor activity produced by administering NMDA antagonists into the VTA is dopamine-dependent. This was accomplished by evaluating the effect of dopamine antagonists on NMDA antagonist-induced motor stimulation, and by examining the capacity of NMDA antagonist to alter dopamine transmission in mesocorticolimbic dopamine axon terminal fields. If dopamine were found to mediate the NMDA antagonist-induced behavioral activation it could be hypothesized that removing excitatory tone from GABAergic interneurons was disinhibiting dopamnergic cells. Alternatively, if dopamine was determined not to mediate the effect of NMDA antagonists, this would implicate disinhibition of GABAergic projections cells. In addition to producing motor activity, the repeated administration of compounds directly into the VTA results in behavioral sensitization (Elliott and Nemeroff, 1986; Kalivas and Duffy, 1990). Thus, daily microinjection of -opioid or neurotensin agonists into the VTA elicits a progressive increase in motor activity that shows cross-sensitization with systemically administered amphetamine-like psychostimulants and is associated with sensitized release of dopamine in the nucleus accumbens. The present study also examined whether the repeated administration of NMDA antagonist into the VTA elicits behavioral sensitization to a subsequent microinjection of NMDA antagonist or to the systemic administration of cocaine. 227 228 Cornish et al. Histology and Data Analysis. The rats not used for biochemical analysis (see above) were administered an overdose of pentobarbitol (⬎100 mg/kg i.p.) and transcardially perfused with 0.9% saline followed by a 10% formalin solution. The brain was removed and placed in 10% formalin for at least 1 week to ensure proper fixation. Brains were then blocked and coronal sections (100 m) were made through the site of cannula implantation with a vibratome. The brains were subsequently stained with cresyl violet and anatomical placement was verified by an individual unaware of the animal’s behavioral response. The StatView statistics package was used to conduct oneway or two-way repeated measures analyses of variance (ANOVA) on all behavioral data. The biochemical measures were statistically evaluated using a one-way ANOVA. The levels of dopamine and its metabolites were evaluated as the dopamine metabolite ratio calculated as follows: (DOPAC ⫹ HVA)/(DOPAC ⫹ HVA ⫹ dopamine). Upon discovery of statistical significance, pairwise factorial analysis was performed using a least-significant difference test (Milliken and Johnson, 1984). Fig. 2. Lack of behavioral effect of blocking AMPA/kainate and metabotropic glutamate receptors in the VTA. The data are shown as the total photocell counts (mean ⫾ S.E.M.) obtained over the 2 h after microinjection. In each drug treatment group all animals received every dose in a counterbalanced design and the data were evaluated using a one-way repeated measures ANOVA. CNQX: N ⫽ 6, horizontal F(5,15) ⫽ 0.35, p ⫽ 0.792; distance, F(5,15) ⫽ 0.31, p ⫽ 0.819; vertical, F(5,15) ⫽ 3.03, p ⫽ 0.034. MCPG: N ⫽ 5, horizontal F(4,12) ⫽ 1.88, p ⫽ 0.187; distance, F(4,12) ⫽ 2.18, p ⫽ 0.143; vertical, F(1,12) ⫽ 1.08, p ⫽ 0.395. *p ⬍ 0.05, compared with saline using a Dunnett’s test for post hoc comparisons. Results Motor Stimulation by Blocking NMDA Receptors in the VTA. Figure 1 shows the dose-dependent motor stimulant response elicited by the microinjection of AP-5 into the VTA. The motor response occurred with a threshold dose between 0.5 and 1.5 nmol and at the highest dose (5.0 nmol) Fig. 3. Blockade of D1 dopamine receptors antagonizes AP-5-induced motor activity only at doses that also inhibit spontaneous motor activity. Data are shown as the mean ⫾ S.E.M. horizontal photocell counts over the 120 min after the injection of intra-VTA injection of AP-5 (5.0 nmol) or saline. Rats were pretreated 15 min prior to intracranial injection with saline (1.0 ml/kg i.p.) or various doses of SCH-23390. A, upper lines refer to the mean ⫾ S.E.M. photocell counts after saline (i.p.) and AP-5 in the VTA, and the filled squares correspond to AP-5 plus increasing doses of SCH-23390. The lower lines refer to treatment saline (i.p.) and saline (intra-VTA) and the open squares refer to increasing doses of SCH-23390 plus saline (intra-VTA). B, data in A normalized to percentage of change from saline control. This was done to more readily compare the effect of D1 blockade between the control and AP-5-induced motor responses. Data were evaluated using an overall two-way ANOVA (treatment, F(1,4) ⫽ 0.89, p ⫽ 0.348; dose, F(4,57) ⫽ 11.98, p ⬍ 0.001; interaction, F(4,57) ⫽ 0.30, p ⫽ 0.874) followed by individual comparisons of different doses of SCH-23390 to saline within each treatment (i.e., saline or AP-5) using a paired Student’s t test with probability values adjusted according to the Bonferonni method (Milliken and Johnson, 1984). *p ⬍ 0.05, comparing each dose of SCH-23390 with saline. Downloaded from jpet.aspetjournals.org at ASPET Journals on May 5, 2017 Fig. 1. Blockade of NMDA receptors in the VTA with AP-5 produces a dose-dependent elevation in motor activity. Rats were adapted to the photocell box for 60 min, injected with various doses of AP-5 into the VTA at time zero, and motor activity was monitored for 2 h. Left, time course (mean value). Right, total photocell counts (mean ⫾ S.E.M.) accumulated over 2 h after injection. All subjects (N ⫽ 7) received each dose in counterbalanced order. The time course data were evaluated using a two-way ANOVA with repeated measures over time [dose F(3,24) ⫽ 3.98, p ⫽ 0.020; time F(11,264) ⫽ 113.84, p ⬍ 0.001; interaction F(33,264) ⫽ 4.72, p ⬍ 0.001], and the total counts were evaluated using a one-way repeated measures ANOVA [horizontal F(3,27) ⫽ 12.67, p ⬍ 0.001; distance F(3,27) ⫽ 16.13, p ⬍ 0.001; vertical F(3,27) ⫽ 5.57, p ⫽ 0.007]. *p ⬍ 0.05 comparing AP-5 to saline using a Dunnett’s test for post hoc comparison. NMDA Antagonists in VTA coadministration of the -opioid DAMGO into the VTA (Fig. 4C). DAMGO microinjection into the VTA did not elevate rearing behavior. Figure 5 shows that while the microinjection of either AP-5 or DAMGO into the VTA elicited a motor stimulant response, only DAMGO microinjection was associated with an increase in dopamine metabolism in the nucleus accumbens and striatum. Neither AP-5 nor DAMGO elevated dopamine metabolism in the prefrontal cortex. Lack of Behavioral Sensitization Produced by Repeated NMDA Antagonist Microinjection into the VTA. Similar to DAMGO, other compounds such as neurotensin or Substance P elicit a dopamine-dependent activation of motor activity when microinjected into the VTA, and the repeated administration of all of these compounds results in long-term behavioral sensitization of the motor stimulant effect (for review, see Kalivas, 1993). Figure 6 shows that the daily administration of the competitive NMDA antagonist CPP into the VTA did not produced behavioral sensitization to a challenge microinjection of CPP made 7 days later. Figure 6A shows that, similar to AP-5, the acute administration of CPP produced a significant dose-dependent elevation in motor activity. Figure 6B shows that 1 week after the last daily injection of CPP a subsequent microinjection of CPP (0.1 nmol) produced a similar increase in motor activity in all three daily treatment groups, indicating that neither tolerance nor sensitization of the motor response was elicited by daily CPP injections. One to 2 weeks after the CPP challenge microinjection (i.e., at 2–3 weeks after the last daily microinjection of saline or CPP) rats were injected with cocaine (15 mg/kg i.p.). Figure 6C shows that the increase in horizontal photocell counts and distance traveled elicited by cocaine was significantly reduced in rats retreated with the highest daily dose of CPP. The time course data in Fig. 6D reveal that the blunted behavioral response to cocaine occurred during the first hour after cocaine administration. Three days following the final injection of cocaine, some rats were decapitated and the level of dopamine quantified in the nucleus accumbens to determine whether repeated administration of CPP into the VTA had damaged the dopamine projection. It was found Fig. 4. Behavioral activation by AP-5 is blocked by coadministration of baclofen, but not OFQ. Subjects were injected with a mixture of OFQ or baclofen plus AP-5 or baclofen into the VTA. A, mean ⫾ S.E.M. photocell counts over 2 h following baclofen plus AP-5. Each animal received all four treatments in each group (N ⫽ 6) and the data were evaluated using a one-way repeated measures ANOVA (horizontal, F(3,23) ⫽ 13.60, p ⬍ 0.001; distance, F(3,23) ⫽ 16.13, p ⬍ 0.001; vertical, F(3,23) ⫽ 5.57, p ⫽ 0.007). B, data for subjects treated with OFQ plus AP-5 (N ⫽ 7; horizontal, F(3,27) ⫽ 10.81, p ⬍ 0.001; distance, F(3,27) ⫽ 10.87, p ⬍ 0.001; vertical, F(3,27) ⫽ 3.84, p ⫽ 0.028). C, data for subjects treated with OFQ plus DAMGO (N ⫽ 6; horizontal, F(3,23) ⫽ 13.35, p ⬍ 0.001; distance, F(3,23) ⫽ 12.63, p ⬍ 0.001; vertical, F(3,23) ⫽ 0.46, p ⫽ 0.986). *p ⬍ 0.05, comparing all treatments to saline/saline using a least-significant difference test (Milliken and Johnson, 1984). ⫹ p ⬍ 0.05, comparing saline plus AP-5 or DAMGO with OFQ or baclofen plus AP-5 or DAMGO. Downloaded from jpet.aspetjournals.org at ASPET Journals on May 5, 2017 significant behavioral activation endured for 45 min after AP-5 administration. A similar dose-dependent psychomotor stimulant effect by AP-5 was measured in estimates of both locomotion (distance) and rearing. Figure 2 reveals that intra-VTA administration of the nonNMDA ionotropic glutamate receptor antagonist CNQX did not alter locomotor activity over a dose range from 0.03 to 10.0 nmol. However, a biphasic effect was measured on rearing behavior with a significant increase being induced by 1.0 nmol of CNQX. The nonselective mGluR competitive antagonist MCPG was without effect on locomotor or rearing behavior over a dose range of 1.0 to 30.0 nmol. Lack of Dopamine Involvement in Motor Activity Induced by Blocking NMDA Receptors. The systemic administration of the dopamine D1 receptor antagonist SCH23390 has been shown previously to block the motor response elicited by dopamine-dependent psychomotor stimulants such as amphetamine and cocaine (White et al., 1998). Figure 3 shows that only at doses that suppress spontaneous motor activity was the systemic administration of SCH-23390 effective at inhibiting the motor response elicited by intra-VTA administration of AP-5 (5.0 nmol). Evaluation of the data transformed to percentage of change from systemic saline administration (Fig. 3B) reveals that at a dose as low as 0.03 mg/kg SCH-23390 significantly reduced both spontaneous and AP-5-induced motor activity. However, a dose of0.3 mg/kg was required to completely block AP-5-induced locomotion. Previous studies have shown that stimulating GABAB receptors inhibits the firing frequency of both dopaminergic and GABAergic cells in the VTA (Johnson and North, 1992). In contrast, stimulating OFQ receptors in the VTA selectively inhibits dopamine neurons (Murphy and Maidment, 1999). Figure 4 shows that while the coadministration of baclofen with AP-5 into the VTA inhibited AP-5-induced locomotor activity, OFQ was without effect on AP-5-induced locomotion. In contrast to locomotion, OFQ partly antagonized AP-5-induced rearing behavior. The biological effectiveness of the dose of OFQ used was verified by showing that OFQ inhibited the motor stimulant response elicited by the 229 230 Cornish et al. that the repeated injection of CPP did not alter the levels of dopamine (saline, N ⫽ 4, 301 ⫾ 36 pmol/mg of protein; 0.1 nmol CPP, N ⫽ 5, 376 ⫾ 73 pmol/mg). Histology. Figure 7A reveals the location of cannulae tips in the VTA of rats used in this study. The cannulae tips were in the nucleus parabrachialis pigmentosus and nucleus paranigralis, ranging mediolaterally from the lateral aspects of the interpeduncular nucleus to the medial edge of the substantia nigra, pars compacta. The micrograph in Fig. 7C shows an injection site from an animal receiving daily CPP (0.1 nmol) in the sensitization study (see above), and the high-power micrograph in Fig. 7D reveals no neurotoxicity produced by this treatment beyond the mechanical damage caused by penetration of the injection needle. The micrograph in Fig. 7B is an example of an animal having cannulae placement dorsal to the VTA that did not demonstrate a motor stimulant response after microinjection of AP-5. Discussion The present study reveals that inhibition of NMDA receptors in the VTA elicits a dose-dependent stimulation of motor activity. Consistent with previous studies (Mathe et al., 1998; Svensson et al., 1998), except for a biphasic effect on rearing the microinjection of the AMPA/kainate antagonist CNQX did not alter motor activity over the dose range examined (see below). Likewise, blockade of mGluRs in the VTA with the subtype nonselective antagonist MCPG was without effect on motor behavior. Lack of Involvement by Dopamine Neurons in the Motor Stimulant Response to Intra-VTA AP-5 Administration. The VTA contains dopamine cells that project to forebrain nuclei (Fallon and Moore, 1978), and the microinjection of a variety of neurotransmitter agonists and antagonists into the VTA stimulates motor activity by increasing Downloaded from jpet.aspetjournals.org at ASPET Journals on May 5, 2017 Fig. 5. Motor response elicited by the NMDA antagonist AP-5 is not associated with increased dopamine metabolism in the nucleus accumbens, striatum, or prefrontal cortex. A, neurochemical response 30 min following microinjection of saline (N ⫽ 8), AP-5 (5.0 nmol; N ⫽ 5), or DAMGO (0.1 nmol; N ⫽ 7). The data are shown as the mean ⫾ S.E.M. dopamine metabolite ratio (DOPAC ⫹ HVA)/(DOPAC ⫹ HVA ⫹ dopamine). The raw data (pmol/mg of protein) following saline treatment for each brain region are as follows: accumbens, dopamine ⫽ 390.7 ⫾ 36.0, DOPAC ⫽ 71.9 ⫾ 7.6, HVA ⫽ 24.0 ⫾ 1.3; striatum, dopamine ⫽ 731.3 ⫾ 53.6, DOPAC ⫽ 53.9 ⫾ 2.7, HVA ⫽ 25.7 ⫾ 2.1; and prefrontal cortex, dopamine ⫽ 5.9 ⫾ 0.7, DOPAC ⫽ 1.8 ⫾ 0.1, HVA ⫽ 2.0 ⫾ 0.2. B, motor stimulant response (mean ⫾ S.E.M. horizontal photocell counts) over 30 min following microinjection before subjects were decapitated for neurochemical analysis. All data were evaluated using a one-way ANOVA and drug treatments compared with saline using a Dunnett’s test. *p ⬍ 0.05, comparing AP-5 or DAMGO with saline. mesocorticolimbic dopamine transmission (Kalivas, 1993; Karreman et al., 1996; Westerink et al., 1996). Surprisingly, three experiments in the present study revealed that the motor activity elicited by NMDA antagonists in the VTA is likely independent of effects on dopamine transmission. 1) Systemic or intra-accumbens administration of the dopamine D1 receptor antagonist SCH-23390 inhibits the motor stimulant effect of amphetamine-like psychostimulants (Baker et al., 1998; White et al., 1998), and the motor response to intra-VTA administration of AP-5 was antagonized only in doses sufficient to inhibit spontaneous motor activity. 2) The administration of OFQ into the VTA is known to selectively inhibit dopamine cells (Murphy and Maidment, 1999) and OFQ did not inhibit AP-5-induced locomotor activity, but did antagonize the motor stimulant response elicited by the -opioid DAMGO, which is known to increase motor activity via activation of dopamine cells (Cador et al., 1989; Kalivas and Duffy, 1990). 3) Also, in contrast with stimulating -opioid receptors, inhibiting NMDA receptors in the VTA elicited a motor stimulant response that did not increase measures of dopamine metabolism in dopamine axon terminal fields. A Role for GABAergic Neurons in the VTA in the Motor Stimulant Response to Intra-VTA AP-5. The apparent lack of involvement by increased activity of dopamine neurons is consistent with the findings that competitive NMDA antagonists administered into the ventral mesencephalon decrease burst firing of dopamine neurons (Overton and Clark, 1992; Chergui et al., 1993; Christoffersen and Meltzer, 1995), and a decrease in burst firing would be expected to decrease axon terminal field dopamine release (Suaud-Chagny et al., 1992). Also, in vivo microdialysis studies find that the administration of AP-5 into the VTA does not alter the extracellular levels of dopamine in the VTA, nucleus accumbens, or prefrontal cortex (Enrico et al., 1998; Svensson et al., 1998; Kretschmer, 1999; Fu et al., 2000). The substantive data that the administration of competitive NMDA antagonists into the VTA does not alter dopamine firing frequency or mesocorticolimbic dopamine transmission point to possible involvement of GABAergic neurons in the VTA. While the synaptic organization and function of GABAergic interneurons in the VTA is partly understood, there is a significant population of GABAergic projection neurons that have been less well characterized. GABAergic neurons in the ventral mesencephlon project to a number of nuclei in parallel with dopamine neurons, including the prefrontal cortex and nucleus accumbens (Thierry et al., 1980; Van Bockstaele and Pickel, 1995; Steffensen et al., 1998). The pharmacological administration of glutamate agonists or stimulating cortical glutamatergic afferents depolarizes and stimulates firing in both nondopaminergic and dopaminergic neurons in the VTA (Johnson et al., 1992). Moreover, NMDA antagonists reduce the spontaneous firing activity of nondopamine cells in the VTA (Steffensen et al., 1998; Bonci and Malenka, 1999). If these nondopaminergic cells are GABAergic interneurons this action would be expected to increase dopamine cell activity via disinhibition; however, the apparent lack of dopamine involvement in AP-5-induced motor activity argues that this is not a primary action. Rather, it can be postulated that the NMDA antagonist is decreasing the activity of GABAergic projection neurons, thereby removing inhibitory tone in forebrain nuclei where GABAergic tone NMDA Antagonists in VTA 231 is known to inhibit spontaneous and pharmacologically induced behavior (Swerdlow et al., 1990; Xi and Stein, 2000). If a nondopaminergic mechanism is supported by subsequent studies, it offers an alternative route whereby neurotransmission in the VTA can regulate behavioral activation. Possible glutamatergic afferents to the VTA that could contribute to such a mechanism include the prefrontal cortex and medial aspects of the subthalamic nucleus and pedunculopontine region (Smith et al., 1996; Carr and Sesack, 2000a). The present study cannot distinguish which of the afferents may provide preferential regulation of GABAergic versus dopaminergic neurons in the VTA. However, recent studies from Sesack and coworkers reveal the likelihood that glutamatergic afferents from the prefrontal cortex synapse on GABAergic projection neurons in the VTA (Carr and Sesack, 2000a,b). Repeated NMDA Antagonist Administration and Cocaine-Induced Motor Activity. The motor stimulant response elicited by the microinjection of drugs into the VTA that increase dopamine transmission undergoes sensitization following repeated intra-VTA administration (for review, see Kalivas, 1993). Moreover, behavioral sensitization produced by repeated intra-VTA injections of neurotensin, -opioid, or D1 agonist results in behavioral cross-sensitization to systemically administered psychostimulants such as amphetamine and cocaine (Kalivas, 1993; Pierce et al., 1996). Behavioral sensitization elicited by intra-VTA and systemically administered drugs arises in part from stimulating NMDA receptors in the VTA (Kalivas and Alesdatter, 1993; Vezina and Queen, 2000). Given these data it is perhaps not surprising that repeated administration of NMDA antagonist into the VTA did not elicit behavioral sensitization to a subsequent challenge with either intra-VTA CPP or systemic cocaine administration. However, it is important to note that although the daily dosing regimen is similar to that required for other drugs to elicit behavioral sensitization when microinjected into the VTA (see Elliott and Nemeroff, 1986, for discussion of daily versus less frequent repeated intra-VTA adminstration), and the dose range used has been shown previously to be behaviorally active (Kalivas and Alesdatter, 1993), a different dosage regimen may have elicited behavioral sensitization. Not only did repeated NMDA antagonist not elicit behavioral sensitization but also the response to systemic cocaine was reduced in subjects pretreated with daily intra-VTA administration of NMDA antagonist. The mechanism mediating the inhibition of cocaine-induced motor activity was not determined in the present report. However, it does not appear to be related to neurotoxicity produced by repeated intra-VTA injections of CPP for two reasons. 1) No toxicity was apparent from Nissl-stained tissue containing the injection site, and 2) the tissue levels of dopamine in the nucleus accumbens were not different between animals injected with daily saline compared with daily CPP-injected subjects. This argues that long-lasting neuroadaptations are produced by the repeated removal of NMDA tone to neurons in the VTA. Since the motor stimulant response to an acute injection of cocaine arises to a great extent by increasing dopamine transmission in the nucleus accumbens (Kelly and Iversen, 1976), it is possible that repeated removal of NMDA tone on dopamine neurons has reduced the Downloaded from jpet.aspetjournals.org at ASPET Journals on May 5, 2017 Fig. 6. Repeated microinjection of the NMDA antagonist CPP into the VTA does not produce behavioral sensitization, but does produce an enduring decrease in cocaine-induced motor activity. Rats were injected into the VTA daily for 3 days with saline (N ⫽ 13) or CPP (0.03 nmol, N ⫽ 11, or 0.1 nmol, N ⫽ 17), and all subjects were subsequently challenged with CPP (0.1 nmol) or cocaine (15 mg/kg i.p.). A, mean ⫾ S.E.M. photocell counts over 120 min after the first daily injection. B, data from the CPP challenge. C, data from the cocaine challenge (arrow indicates time of injection). Total photocell counts were evaluated using a two-way ANOVA with repeated measures over days (horizontal: treatment, F(3,38) ⫽ 1.70, p ⫽ 0.197; day, F(2,76) ⫽ 74.67, p ⬍ 0.001; interaction, F(4,76) ⫽ 4.06, p ⫽ 0.005; distance: treatment, F(3,38) ⫽ 1.32, p ⫽ 0.279; day, F(2,76) ⫽ 70.38, p ⬍ 0.001; interaction, F(4,76) ⫽ 3.50, p ⫽ 0.011; vertical: treatment, F(3,38) ⫽ 0.60, p ⫽ 0.554; day, F(2,76) ⫽ 10.30, p ⬍ 0.001; interaction, F(4,76) ⫽ 1.41, p ⫽ 0.240). D, time course data corresponding to the cocaine challenge data (treatment, F(2,38) ⫽ 3.50, p ⫽ 0.040; time, F(11,418) ⫽ 67.84, p ⬍ 0.001; interaction, F(20,418) ⫽ 2.85, p ⬍ 0.001). *p ⬍ 0.05, comparing the CPP with the saline treatment groups using a least-significant difference test (Milliken and Johnson, 1984). 232 Cornish et al. mimicked by blockade of either the AMPA/kainate or mGluR subtypes of glutamate receptor. The motor stimulant response is not mediated by enhancing dopamine transmission and presumably involves the removal of NMDA-mediated excitatory stimulation of GABAergic projection neurons in the VTA. The finding that repeated NMDA antagonist administration into the VTA reduced the motor stimulant effect of a subsequent injection of cocaine may indicate a novel mechanism for reducing the effects of cocaine by inducing long-term neuroadaptations that counter the pharmacological action of cocaine. Indeed, many reports have demonstrated that psychostimulant-induced behavioral sensitization is blocked by pretreatment with NMDA antagonists (for review, see Wolf, 1998). Acknowledgments excitability of dopamine cells (Johnson and North, 1992). Alternatively, repeated reduction in NMDA-mediated excitatory tone to GABAergic neurons in the VTA may alter the inhibitory tone provided by GABAergic interneurons to dopamine cells. Rearing versus Locomotion. In two instances distinctions between drug effects on rearing and locomotion were observed: 1) CNQX administration into the VTA elicited a dose-related biphasic effect on rearing without altering locomotion, and 2) OFQ antagonized AP5-induced rearing without altering the locomotor response to AP-5. This distinction between rearing and locomotion reveals that different substrates in the VTA mediate each behavior. Moreover, the capacity of OFQ to antagonize rearing behavior indicates likely involvement of dopamine transmission. This could arise from either 1) direct or indirect activation of dopamine cells, which seems unlikely given the lack of effect on measures of dopamine transmission (although an effect on dopamine transmission in an axon terminal field not evaluated in this study is possible); or 2) dopamine transmission is permissive to rearing behavior. While NMDA antagonists do not stimulate dopamine neurons to increase terminal field dopamine transmission, dopaminergic tone may be necessary to manifest rearing in response to NMDA receptor blockade in the VTA. Conclusions The inhibition of NMDA glutamate receptors in the VTA produces an increase in motor activity. This effect is not We thank Carol Heissenbuttle for assistance in preparing the manuscript, Dr. David Grandy for the generous gift of orphanin, and National Institute on Drug Abuse for providing cocaine HCl. References Baker DA, Fuchs RA, Specio SE, Khroyan TV and Neisewander JL (1998) Effects of intraaccumbens administration of SCH-23390 on cocaine induced locomotion and conditioned place preference. Synapse 30:181–193. Bonci A and Malenka R (1999) Properties and plasticity of excitatory synapses on dopaminergic and GABAergic cells in the ventral tegmental area. J Neurosci 19:3723–3730. Cador M, Rivet J-M, Kelley J-M, LeMoal M and Stinus L (1989) Substance P, neurotensin and enkephalin injections into the ventral tegmental area: a comparative study on dopamine turnover in several forebrain structures. Brain Res 486:357–363. Carr DB and Sesack SR (2000a) Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 20:3864 –3873. Carr DB and Sesack SR (2000b) GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex. Synapse 38:114 –123. Chergui K, Charlety PJ, Akaoka H, Saunier CF, Brunet J-L, Buda M, Svensson TH and Chouvet G (1993) Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci 5:137– 144. Christoffersen CL and Meltzer LT (1995) Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptors on substantia nigra dopamine neurons: possible preferential role for N-methyl-D-aspartate receptors. Neuroscience 67: 373–381. Elliott PJ and Nemeroff CB (1986) Repeated neurotensin administration in the ventral tegmental area: effects on baseline and d-amphetamine-induced locomotor activity. Neurosci Lett 68:239 –244. Enrico P, Bouma M, de Vries JB and Westerink BHC (1998) The role of afferents to the ventral tegmental area in the handling stress-induced increase in the release of dopamine in the medial prefrontal cortex: a dual-probe microdialysis study in the rat brain. Brain Res 779:205–213. Fallon JH and Moore RY (1978) Catecholamine innervation of basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and striatum. J Comp Neurol 180:545–580. Fu Y, Matta S, Gao W, Brower V and Sharp B (2000) Systemic nicotine stimulates dopamine release in nucleus accumbens: re-evaluation of the role of N-methyl-Daspartate receptors in the ventral tegmental area. J Pharmacol Exp Ther 294: 458 – 465. Johnson SW, Seutin V and North RA (1992) Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. Science (Wash DC) 258:665– 667. Kalivas PW (1993) Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev 18:75–113. Kalivas PW and Alesdatter JE (1993) Involvement of NMDA receptor stimulation in the VTA and amygdala in behavioral sensitization to cocaine. J Pharmacol Exp Ther 267:486 – 495. Kalivas PW and Duffy P (1990) Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. J Neurosci 10: 2940 –2949. Karreman M, Westerink BHC and Moghaddam B (1996) Excitatory amino acid receptors in the ventral tegmental area regulate dopamine release in the ventral striatum. J Neurochem 67:601– 607. Kelley AE, Stinus L and Iversen SD (1979) Behavioral activation induced in the rat by substance P infusion into the ventral tegmental area: implication of dopaminergic A10 neurons. Neurosci Lett 11:335–339. Kelly PH and Iversen SD (1976) Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 40:45–56. Kretschmer BD (1999) Modulation of the mesolimbic dopamine system by glutamate: role of NMDA receptors. J Neurochem 73:839 – 848. Latimer LG, Duffy P and Kalivas PW (1987) Mu opioid receptor involvement in Downloaded from jpet.aspetjournals.org at ASPET Journals on May 5, 2017 Fig. 7. Histological verification of cannulae placement in the VTA and lack of neurotoxicity by repeated intra-VTA microinjection of CPP. A, location of cannulae tips in the VTA of animals used in the dose-response studies and experiments involving baclofen and OFQ. The numbers on the left of the drawings indicate the distance (mm) of the coronal section rostral to interaural zero (Paxinos and Watson, 1986). B, micrograph showing an example of cannulae tips that were located outside of the VTA where the microinjection of AP-5 did not elicit a motor stimulant response. C, micrograph illustrating cannulae placement in the VTA. D, high-power micrograph corresponding to the area in the box in C and demonstrates a lack of cell death at a site of repeated CPP administration into the VTA. While damage was produced by mechanical penetration of the injection needle, the adjacent neuropil appears healthy. The solid arrows indicate healthy cells, while the striped arrows indicate the location of damage by injection needle. IP, interpeduncular nucleus; SNp, substantia nigra, pars compacta; SNr, substantia nigra, reticulat; VTA, ventral tegmental area. Scale bar, 1 mm (B and C), 100 m (D). NMDA Antagonists in VTA acids in the ventral tegmental area for central actions of non-competitive NMDAreceptor antagonists and nicotine. Amino Acids 14:51–56. Swanson CJ and Kalivas PW (2000) Regulation of locomotor activity by metabotropic glutamate receptors in the nucleus accumbens and ventral tegmental area. J Pharmacol Exp Ther 292:406 – 414. Swerdlow NR, Braff DL and Geyer MA (1990) GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats. Brain Res 532:146 –154. Thierry A, Deniau J, Herve D and Chevalier G (1980) Electrophysiological evidence for non-dopaminergic mesocortical and mesolimbic neurons in the rat. Brain Res 201:210 –214. Van Bockstaele EJ and Pickel VM (1995) GABA-containing neurons in the ventral tegmental area project to the nucleus accumbens in the rat brain. Brain Res 682:215–221. Vezina P and Queen A (2000) Pharmacological reversal of behavioral and cellular indices of cocaine sensitization in the rat. Psychopharmacology 151:184 –191. Westerink BHC, Kwint H-F and deVries JB (1996) The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16:2605–2611. White FJ, Joshi A, Koeltzow TE and Hu X-T (1998) Dopamine receptor antagonists fail to prevent induction of cocaine sensitization. Neuropsychopharmacology 18: 26 – 40. Wolf ME (1998) The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 54:679 –720. Xi Z and Stein E (2000) Increased mesolimbic GABA concentration blocks heroin self administration in the rat. J Pharmacol Exp Ther 294:613– 619. Yang C, Seamans J and Gorelova N (1999) Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 21:161–194. Yoshida M, Yokoo H, Nakahara K, Tomita M, Hamada N, Ishikawa M, Hatakeyama J, Tanaka M and Nagatsu I (1997) Local muscimol disinhibits mesolimbic dopaminergic activity as examined by brain microdialysis and Fos immunohistochemistry. Brain Res 767:356 –360. Address correspondence to: Peter Kalivas, Ph.D., Department of Physiology and Neuroscience, P.O. Box 250677, Medical University of South Carolina, Charleston, SC 29425. E-mail: [email protected] [email protected] Downloaded from jpet.aspetjournals.org at ASPET Journals on May 5, 2017 enkephalin activation of dopamine neurons in the ventral tegmental area. J Pharmacol Exp Ther 241:328 –337. Mathe J, Nomikos G, Schilstrom B and Svensson T (1998) Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemin dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res 51:583–592. Milliken GA and Johnson DE (1984) Analysis of Messy Data. Volume I: Designed Experiments. Lifetime Learning Publications, Belmont, CA. Murphy N and Maidment N (1999) Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. J Neurochem 73:179 – 186. Narayanan S, Willins D, Dalia A, Wallace L and Uretsky N (1996) Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol Biochem Behav 54:567– 573. Overton P and Clark D (1992) Iontophretically administered drugs acting at the N-methyl-D-aspartate receptor modulate burst firing in A9 dopamine neurons in the rat. Synapse 10:131–140. Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York. Pellegrino LK, Pellegrino AS and Cushman AJ (1979) A Stereotaxic Atlas of the Rat Brain. Plenum Press, New York. Pierce RC, Born B, Adams M and Kalivas PW (1996) Repeated intral-ventral tegmental area administration of SKF-38393 induces behavioral and neurochemical sensitization to a subsequent cocaine challenge. J Pharmacol Exp Ther 278:384 – 392. Robinson TE and Berridge KC (1993) The neural basis of drug craving: an incentivesensitization theory of addiction. Brain Res Rev 18:247–291. Smith Y, Charara A and Parent A (1996) Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminal in the squirrel monkey. J Comp Neurol 364:231–253. Steffensen SC, Svingos AL, Pickel VM and Henriksen SJ (1998) Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. Neuroscience 18:8003– 8015. Suaud-Chagny MF, Chergui K, Chouvet G and Gonon F (1992) Relationship between dopamine release in the rat nucleus accumbens and the discharge activity of dopaminergic neurons during local in vivo application of amino acids in the ventral tegmental area. Neuroscience 49:63–72. Svensson T, Mathe J, Nomikos G and Schilstrom B (1998) Role of excitatory amino 233